Optune Lua (Novottf-200t)
Payments companies reported to CMS as associated with Optune Lua (Novottf-200t). "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Optune Lua (Novottf-200t), per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Optune Lua (Novottf-200t)
These are the largest totals companies reported as associated with Optune Lua (Novottf-200t). They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Eshan Patel | Somerville, NJ | Hematology & Oncology | $103,748.83 |
| Ticiana Leal | Atlanta, GA | Hematology & Oncology | $89,216.69 |
| Wade Iams | Nashville, TN | Hematology & Oncology | $76,342.59 |
| Martin Dietrich | Rockledge, FL | Hematology & Oncology | $33,673.50 |
| Simon Khagi | Newport Beach, CA | Hematology & Oncology | $32,456.95 |
| Eric Nadler | Dallas, TX | Medical Oncology | $32,337.38 |
| Stephen Chun | Houston, TX | Radiation Oncology | $27,086.28 |
| Mary Fidler | Chicago, IL | Medical Oncology | $24,104.77 |
| Patrick Forde | Baltimore, MD | Hematology & Oncology | $21,645.46 |
| Richa Dawar | Deerfield Beach, FL | Hematology & Oncology | $21,455.00 |
Prescribed Optune Lua (Novottf-200t)?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.